• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

For the new healthcare landscape: A new Formulary brand


In just 1 year, with the rollout of the Affordable Care Act, the healthcare landscape has undergone its most far-reaching change in decades.

In just 1 year, with the rollout of the Affordable Care Act, the healthcare landscape has undergone its most far-reaching change in decades.

In light of this and all the revolutions, large and small, that are taking place in every aspect of healthcare practice, Formulary understands how important it is to develop new and better connections between patients, care providers, and payers. That is why we are launching FormularyWatch, a new brand aimed at helping you-the clinical pharmacist and the hospital and managed care pharmacy decision-maker-manage day-to-day clinical operations.

FormularyWatch will feature immediate, easily accessible data and information such as FDA approvals, a drug pipeline digest, consideration of drugs in context, drug evaluation updates, news analysis, experience briefs, readers’ blog, policy commentary, and more.

FormularyWatch provides our readers with a timely, unbiased, executive-level summary reference of newly emerging therapies, as well as insights into the most relevant safety information, landmark study data, and disease-specific evidence,” said FormularyWatch Clinical Editor David Calabrese, RPh, MHP. “This brand should serve as an ideal resource for today’s busy clinical and administrative leaders taxed with drug-evaluation and clinical decision-making responsibilities.

“Given the rapid transformations taking place within our healthcare industry and the resulting pressures and challenges, pharmacy and medical professionals are demanding high integrity, easily accessible resources like FormularyWatch to help support day-to-day clinical functions,” said Calabrese, who is also VP and chief pharmacy officer at Catamaran, Worcester, Mass., and clinical assistant professor at Northeastern University Bouve College of Health Sciences School of Pharmacy, Boston.

We are always looking for more effective ways to serve our readers. As the latest electronic evolution of Formulary journal, FormularyWatch provides easy access to breaking news and timely information and commentary in a way that no print publication can achieve. Therefore, going forward, FormularyWatch will replace the print version of Formulary journal. It is our hope that as you explore FormularyWatch, you will come to see it as an increasingly valued resource.

The editorial staff of FormularyWatch welcomes all suggestions of additional ways we can improve our service to you, our readers. As you become acquainted with the newest version of the Formulary resource you have turned to in the past, please e-mail your ideas, thoughts, and comments to Content Channel Director Julie Miller, julie.miller@advanstar.com. We look forward to hearing from you.

Follow us on Twitter @Formulary_News

Like us on Facebook https://www.facebook.com/Formulary

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.